MDA-MB-436 - Cell Line (ID:50333)
| HMS LINCS ID: | 50333 |
| Name: | MDA-MB-436 |
| Alternative Names: | |
| LINCS ID: | LCL-1470 |
| Alternative ID: | CLO_0007639 |
| Parent Cell Line: | |
| Reference Source: | ATCC HTB-130 |
| Organism: | Homo sapiens |
| Organ: | breast |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | female |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:3458, adenocarcinoma |
| Details of Disease: | breast adenocarcinoma |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | COSS1240172 |
| Verification Reference Profile: | |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | From MGH/CMT as specified by cell provider: Leibovitz's L-15 medium with 10 mcg/ml insulin, 16 mcg/ml glutathione, 90%; fetal bovine serum, 10%. Subculturing: Subcultures are prepared by scraping. Remove spent medium, add 3 to 5 ml of fresh medium, dislodge cells from the floor of the flask, aspirate and dispense into new flasks. Subculture every 6 to 8 days. Subcultivation ratio: A subcultivation ratio of 1:2 is recommended |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2012-07-31 |
| Most Recent Update: | 2016-04-04 |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20120 | Metrics other than potency reveal systematic variation in responses to cancer drugs | Analysis |
| 20137 | Basal profile of receptor tyrosine kinase signaling network measured by ELISA | ELISA |
| 20138 | Cell signaling response to growth factors measured by high throughput microscopy | Microscopy/Imaging |
| 20140 | Cell signaling response to growth factors measured by ELISA | ELISA |
| 20268 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. | Analysis |
| 20269 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. | Analysis |
| 20343 | Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values | Microscopy/Imaging |
| 20344 | Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics | Analysis |
| 20348 | Breast Cancer Profiling Project, Gene Expression 1: Baseline mRNA sequencing on 35 breast cell lines | RNA-Seq |
| 20352 | Breast Cancer Profiling Project – Proteomics 1: 1 total proteome dataset for a 35-cell line breast cancer panel under basal conditions | Proteomics |
| 20353 | Breast Cancer Profiling Project – Proteomics 2: 1 phosphoproteome dataset (including phosphotyrosine enrichment) for a 35-cell line breast cancer panel under basal conditions | Proteomics |
| 20354 | Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values | Microscopy/Imaging |
| 20355 | Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics | Analysis |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Catalog ID | Provider Batch ID |
|---|---|---|---|
| 50333-1 | ATCC | HTB-130 | |
| 50333-2 | ATCC | HTB-130 |